Eli Lilly and Company (NYSE: LLY) has produced fresh data that could widen its lead in the race to dominate both obesity and type 2 diabetes treatment. The company’s experimental “triple G” drug, retatrutide, has cleared its first late-stage study in diabetes patients, showing substantial improvements in both blood sugar control and weight loss, while setting the stage for a more crowded, competitive landscape in the U.S. market. This trial is one of several that will shape how Lilly positions retatrutide in the coming years, and how investors think about its next growth pillar beyond the blockbuster Zepbound.
In the new diabetes trial, patients who had not been taking other diabetes medications started with hemoglobin A1c -c levels between 7% and 9.5%, which is above the typical treatment target for most adults. After 40 weeks on retatrutide, the average HbA1c fell by about 1.7% to 2%, depending on the dose, compared with a placebo group. That drop met the main goal of the trial and puts the drug in line with other leading diabetes therapies, though not quite at the top of Lilly’s own portfolio in terms of blood-sugar reduction. For clinicians, hitting this range with a single agent is meaningful, especially in a population that often struggles to meet targets.
The bigger headline is on weight. At the highest dose, patients who stayed on retatrutide throughout the 40-week period lost, on average, about 16.8% of their body weight, or roughly 37 pounds. When the analysis includes everyone in the trial, including those who stopped treatment, the average weight loss at the highest dose was about 15.3%. For people with type 2 diabetes, who frequently battle rising weight even as they manage blood sugar, those numbers suggest that a single drug could help move the needle on both fronts at once. That overlap of effects is what makes retatrutide interesting from a business as well as a medical standpoint.
Retatrutide works by mimicking three hormones: GLP-1, GIP, and glucagon, which regulate appetite and metabolism. Existing treatments such as tirzepatide, the active ingredient in Lilly’s Zepbound, already target GLP-1 and GIP, while many other obesity and diabetes drugs, including Novo Nordisk’s semaglutide-based Wegovy, mimic only GLP-1. By adding glucagon to the mix, Lilly is trying to push the effect on appetite and energy balance further than current dual-agonist drugs can reach. Earlier trials in obesity patients have already shown weight-loss averages above 24%, which hints that the diabetes population may be just one of several markets where the drug could perform strongly.
Early safety data in the diabetes trial look broadly similar to other injectable diabetes and obesity medicines. The most common problems were gastrointestinal, nausea, diarrhea, and vomiting, occurring in roughly 26.5%, 22.8%, and 17.6% of patients on the highest dose, respectively. A small number of participants reported dysesthesia, an unpleasant nerve sensation, but overall discontinuation rates tied to side effects ran at about 5%, which Lilly’s executives describe as relatively low. That profile matters because higher tolerability can translate into longer treatment duration and more sustained weight loss, both of which are attractive to payers and clinicians.
For Lilly, the results are a step toward building a broader cardiometabolic franchise around next-generation injectables and, eventually, an oral GLP-1-based pill. The company has said it expects to present findings from seven additional phase 3 trials on retatrutide by the end of 2026, including studies in obesity, diabetes, and related conditions such as osteoarthritis. Those readouts will shape when and how Lilly seeks U.S. regulatory approval for retatrutide, though the company has not yet filed for either diabetes or obesity indications. The tentative timeline for U.S. review will likely hinge on how regulators view safety, tolerability, and the incremental benefit over existing therapies.
In the meantime, the drug’s performance feeds into a larger commercial narrative in the U.S. obesity and diabetes market, where Lilly already sells Zepbound and where Novo Nordisk markets semaglutide-based products. Trials of Zepbound have shown patients losing roughly 11% to 13.1% of their body weight at 40 weeks on the highest dose, which is less than the roughly 15% to almost 17% seen with retatrutide in this new diabetes trial. That difference may matter to doctors and patients who view weight loss as a primary goal, especially earlier in the course of diabetes treatment, and could influence which drug Lilly chooses to emphasize in different clinical settings.
Lilly’s leadership has also stressed that not every patient will respond to the same drug in the same way. Some people may prioritize rapid blood-sugar control and stay on Zepbound, while others may switch to or start with retatrutide if losing more weight is a main objective. This kind of “individualized tailoring,” as Lilly executives put it, is becoming central to how clinicians discuss treatment options in diabetes and obesity, rather than offering a one-size-fits-all approach. The diabetes trial results support that narrative by showing that a single drug can move both HbA1c and weight in a clinically meaningful direction.
Beyond Lilly’s own pipeline, the data reinforce why Novo Nordisk and other players are rushing to develop similar triple-hormone therapies. In early 2025, Novo Nordisk agreed to pay up to $2 billion for rights to a Chinese-developed experimental drug, UBT251, that also activates GLP-1, GIP, and glucagon receptors. That drug is much earlier in development, so it will likely take several years before it reaches the U.S. market, but its existence signals that the triple-G concept is now a clear strategic priority for the world’s largest diabetes and obesity-focused company.
Viewed through a business lens, retatrutide’s performance in this diabetes trial gives Lilly more leverage as it prepares for regulatory discussions and pricing negotiations in the U.S. If the drug wins approval for diabetes and then, later, for obesity, it could become a second blockbuster injectable in that category, alongside Zepbound, while Lilly’s oral GLP-1 candidate orforglipron adds another layer of competition with Novo Nordisk’s own oral programs. The 2026 phase 3 readouts will be critical in determining how big that second pillar can become, and how quickly the market can absorb multiple high-effectiveness options. For investors and business readers, the story is less about a single headline number and more about trajectory: Lilly is moving aggressively to lock in a leadership position in triple-hormone therapies, while Novo Nordisk and others try to narrow the gap. As the U.S. regulatory timetable takes shape over the next year, the balance of power in diabetes and obesity treatment could shift again, with retatrutide at the center of the conversation.
